Literature DB >> 10527687

Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.

D Widney1, G Gundapp, J W Said, M van der Meijden, B Bonavida, A Demidem, C Trevisan, J Taylor, R Detels, O Martínez-Maza.   

Abstract

CD27 is a member of the tumor necrosis factor receptor superfamily that is expressed primarily on T cells, as well as on subsets of B cells and NK cells. CD70, which is expressed on activated B and T cells, but not on resting lymphocytes, is a ligand for CD27. Cell surface CD27 can be proteolytically cleaved to produce a 32-kDa soluble CD27 (sCD27) molecule. Elevated levels of sCD27 are seen in a number of disease states and malignancies. Although it has been reported that cerebrospinal fluid sCD27 levels were elevated in people who had AIDS dementia, little is known about CD27 expression in HIV disease. To determine if sCD27 levels were elevated in those with HIV infection, and/or in those with AIDS-associated non-Hodgkin's lymphoma (AIDS-NHL), sCD27 levels were measured in HIV-negative and HIV-positive subjects as well as in people who developed AIDS-NHL. Serum sCD27 levels were seen to be elevated in HIV+ subjects. Furthermore, sCD27 levels were particularly elevated in those subjects who went on to develop AIDS-NHL, with serum sCD27 levels in AIDS-NHL subjects being significantly higher than those in HIV+ subjects who did not develop lymphoma. Most AIDS-NHL cell lines and primary AIDS-NHL tumor specimens expressed both CD27 and its ligand, CD70. The proportion of circulating B cells that expressed cell surface CD27 was substantially reduced in those with HIV infection, and B cells from HIV-infected subjects produced decreased levels of sCD27 in culture. Together, these results indicate that CD27/sCD27 expression is abnormal in HIV infection and suggest that this molecule merits further examination as a potential marker for AIDS-NHL. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527687     DOI: 10.1006/clim.1999.4782

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  38 in total

1.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman
Journal:  Cancer Res       Date:  2011-06-01       Impact factor: 12.701

2.  Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Authors:  Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

3.  Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

Authors:  Yian Gu; Roy E Shore; Alan A Arslan; Karen L Koenig; Mengling Liu; Sherif Ibrahim; Anna E Lokshin; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2010-04-07       Impact factor: 2.506

4.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

5.  T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs.

Authors:  Matthew A Burchill; Beth A Tamburini; Ross M Kedl
Journal:  Eur J Immunol       Date:  2015-08-03       Impact factor: 5.532

6.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

7.  Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.

Authors:  Shehnaz K Hussain; Nancy A Hessol; Alexandra M Levine; Elizabeth Crabb Breen; Kathryn Anastos; Mardge Cohen; Gypsyamber D'Souza; Deborah R Gustafson; Sylvia Silver; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

8.  Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction.

Authors:  Robert C Kalayjian; John Spritzler; Roy M Matining; Susan A Fiscus; Barry H Gross; Isaac R Francis; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

9.  Gamma/Delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid sites following an oral SIV infection of macaques.

Authors:  David A Kosub; Andre Durudas; Ginger Lehrman; Jeffrey M Milush; Christopher A Cano; Mamta K Jain; Donald L Sodora
Journal:  Curr HIV Res       Date:  2008-11       Impact factor: 1.581

10.  Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.

Authors:  Anneclaire J De Roos; Dana K Mirick; Kerstin L Edlefsen; Andrea Z LaCroix; Kenneth J Kopecky; Margaret M Madeleine; Larry Magpantay; Otoniel Martínez-Maza
Journal:  Cancer Res       Date:  2012-07-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.